Clarivate forecasts 2026 adjusted EBITDA of $865 million to $885 million after Life Sciences sale
CLVT•Clarivate forecasts fiscal 2026 revenue of $1.97 billion to $1.99 billion and adjusted EBITDA of $865 million to $885 million, excluding Life Sciences & Healthcare after its $600 million sale. It projects adjusted diluted earnings of $0.73 to $0.77 per share and free cash flow of $320 million to $340 million.
1. 2026 forecasts
Clarivate projects fiscal 2026 revenue of $1.97 billion to $1.99 billion, excluding Life Sciences & Healthcare following its $600 million sale, and adjusted EBITDA of $865 million to $885 million. Adjusted diluted earnings are expected at $0.73 to $0.77 per share, with growth driven by share repurchases. Free cash flow is forecast at $320 million to $340 million, reflecting sale timing and higher one-time costs; for fiscal 2027, free cash flow is projected at $350 million to $400 million, with net leverage around 3.5–3.6 times.
